Sponsor · clinical trials

Eli Lilly and Company clinical trials

Also registered as Eli Lilly & Co

Source: ClinicalTrials.gov, U.S. National Library of Medicine and the EU Clinical Trials Information System (CTIS) — current trials in our USA, Japan, Spain, Germany, China, Canada, France, UK, Italy, Poland, South Korea, Australia, Belgium, Taiwan, Mexico, Brazil, Czechia, Netherlands, Israel, India, Denmark, Turkey, Austria, Singapore, Portugal, Sweden, Norway, Ireland, Switzerland, Egypt and EU (CTIS) registers with Eli Lilly and Company as lead sponsor. Synced 10 Nov 2026

248Current trials

122Recruiting now

108Drugs in these trials

31Trial registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Eli Lilly and Company is the lead sponsor of 248 current clinical trials in our USA, Japan, Spain, Germany, China, Canada, France, UK, Italy, Poland, South Korea, Australia, Belgium, Taiwan, Mexico, Brazil, Czechia, Netherlands, Israel, India, Denmark, Turkey, Austria, Singapore, Portugal, Sweden, Norway, Ireland, Switzerland, Egypt and EU (CTIS) registers. 122 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Tirzepatide, Abemaciclib and Orforglipron. The most-studied condition is Obesity.

Company profiles on this site (news, sites, medicines, approvals): Eli Lilly Ireland (IE) →Eli Lilly and Company (US) →

ClinicalTrials.gov trials by status

Recruiting12253%
Not yet open188%
Active, closed8838%
By invitation42%

Trials by phase

Phase 39340%
Phase 17131%
Phase 24319%
Phase 4115%
Phase 1/263%
Observational63%
Not applicable10%
Phase 2/310%

Clinical trials sponsored by Eli Lilly and Company

232 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease NCT07223593 · Peripheral Arterial Disease Drug: Orforglipron	Phase 3	Recruiting	2025-10	UK, USA, India, China, France, Netherlands, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
A Study of LY3971297 in Participants With Heart Failure NCT07547540 · ClinicalTrials.gov ↗ · Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic	Phase 1	Recruiting	2026-08	USA, Netherlands, Japan
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk NCT07613294 · Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a) Drug: Lepodisiran	Phase 3	Recruiting	2026-06	UK, USA, Spain, Netherlands, Czechia, Australia
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease NCT05509777 · Crohn's Disease Drug: Mirikizumab	Phase 3	Recruiting	2024-03	UK, USA, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Norway, Portugal, Canada, Brazil, Japan, South Korea, Israel
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes NCT07282600 · Overweight, Obesity Drug: Eloralintide	Phase 3	Recruiting	2025-12	USA, India, China, Germany, Spain, Poland, Czechia, Mexico, Japan, South Korea, Taiwan
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: NCT07186101 · Ulcerative Colitis Drugs: Mirikizumab, Zotemtegrast	Phase 2	Recruiting	2025-11	USA, India, China, Germany, Spain, Italy, Netherlands, Denmark, Poland, Austria, Turkey, Canada, Brazil, Mexico, Japan
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease NCT07787169 · Alzheimer Disease, Amyloid, Plaque, Amyloid Drug: LY4405094	Phase 1	Recruiting	2026-09	USA, China, Japan
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis NCT07415044 · Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe Drug: Zotemtegrast	Phase 2	Recruiting	2026-03	USA, India, China, France, Italy, Poland, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain NCT07641504 · Chronic Pain, Low Back Pain Drug: LY4065967	Phase 2	Recruiting	2026-08	USA
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) NCT07157774 · Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)	Phase 3	Recruiting	2025-09	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) NCT07222332 · Diabetes Mellitus, Type 1 Drug: Baricitinib	Phase 3	Recruiting	2026-02	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Czechia, Norway, Portugal, Canada, Brazil, Japan, Australia, Israel
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia NCT07269210 · ClinicalTrials.gov ↗ · Severe Hypertriglyceridemia	Phase 2	Recruiting	2025-12	USA, China, Canada, Japan
A Study of LY4302814 in Healthy Participants NCT07566338 · Healthy	Phase 1	Recruiting	2026-05	USA, Singapore
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) NCT07545759 · Irritable Bowel Syndrome, Diarrhea Drug: Brenipatide	Phase 2	Recruiting	2026-05	UK, USA, China, Germany, Spain, Belgium, Poland, Canada, Mexico, Japan
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) NCT07817875 · Obesity Drug: Tirzepatide	Phase 3	Recruiting	2026-09	USA, Spain, Italy, Belgium, Poland, Portugal, Mexico, South Korea, Taiwan, Israel
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy NCT07654972 · ClinicalTrials.gov ↗ · Obesity, Overweight	Phase 1	Recruiting	2026-06	USA, Singapore
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors NCT05768139 · Breast Cancer, Solid Tumors, Adult Drugs: Abemaciclib, Anastrozole, Exemestane	Phase 1/2	Recruiting	2023-04	Ireland, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Japan
A Study of LY4226695 in Healthy Participants NCT07767487 · Healthy	Phase 1	Recruiting	2026-08	USA, Singapore
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight NCT06937099 · ClinicalTrials.gov ↗ · Crohn's Disease, Obesity or Overweight Drugs: Mirikizumab, Tirzepatide	Phase 3	Recruiting	2025-06	USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Israel
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes NCT07321886 · Obesity, Overweight Drug: Eloralintide	Phase 3	Recruiting	2026-02	UK, USA, India, China, Germany, Belgium, Poland, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study NCT06937086 · Ulcerative Colitis, Obesity or Overweight Drugs: Mirikizumab, Tirzepatide	Phase 3	Recruiting	2025-06	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Israel
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer NCT07287098 · Breast Neoplasms Drugs: Goserelin, Imlunestrant, Tamoxifen	Phase 2	Recruiting	2026-05	Ireland, USA, China, Germany, France, Italy, Belgium, Taiwan
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin NCT07392190 · Overweight, Obesity Drug: Eloralintide	Phase 3	Recruiting	2026-02	USA, India, China, Spain, Belgium, Czechia, Brazil, Mexico, Japan, Taiwan, Australia, Israel
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT07218341 · Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic Drugs: Idelalisib, Pirtobrutinib	Phase 4	Recruiting	2026-03	Ireland, UK, USA, China, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Canada, Japan, Australia, Israel
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma NCT07219173 · Asthma Drug: Brenipatide	Phase 2	Recruiting	2025-10	USA, India, China, Germany, France, Netherlands, Poland, Canada, Brazil, Mexico, Japan
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis NCT07571174 · ClinicalTrials.gov ↗ · Amyotrophic Lateral Sclerosis Drug: LY4256984	Phase 1	Recruiting	2026-05	Germany, Spain, Netherlands, Belgium, Canada
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) NCT07759245 · Pulmonary Disease, Chronic Obstructive Drug: Brenipatide	Phase 2	Recruiting	2026-08	UK, USA, India, China, Germany, France, Denmark, Poland, Austria, Czechia, Canada, Mexico, Japan, South Korea
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) NCT07174336 · Breast Neoplasms, Neoplasm Metastasis Drugs: Abemaciclib, Anastrozole, Exemestane	Phase 3	Recruiting	2025-12	Ireland, UK, USA, China, Germany, France, Spain, Italy, Belgium, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities NCT06672939 · Obesity, Overweight Drug: Orforglipron	Phase 3	Recruiting	2024-11	UK, USA, Italy, Poland, Japan, Israel
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer NCT07213804 · Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms Drugs: Bevacizumab, Carboplatin, Gemcitabine	Phase 3	Recruiting	2025-10	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
A Study of Brenipatide in Participants With Alcohol Use Disorder NCT07219953 · Alcohol Use Disorder Drug: Brenipatide	Phase 3	Recruiting	2025-10	UK, USA, China, Germany, Belgium, Japan, South Korea, Taiwan
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract NCT07218380 · Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis Drugs: Pembrolizumab, Vepugratinib	Phase 3	Recruiting	2025-12	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Denmark, Poland, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease NCT06297590 · Alzheimer Disease	Phase 1	Recruiting	2024-08	UK, USA, Japan
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) NCT07247084 · Obesity Drug: Tirzepatide	Phase 4	Recruiting	2025-11	UK
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) NCT06439277 · Obesity, Weight Gain Drug: Tirzepatide	Phase 3	Recruiting	2024-06	UK, USA, China, Germany, France, Spain, Canada, Mexico, Taiwan, Australia, Israel
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) NCT06857942 · Psoriasis, Overweight or Obesity Drug: Tirzepatide	Phase 4	Recruiting	2025-03	USA
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity NCT07794579 · Overweight, Prediabetic State, Prehypertension Drug: Orforglipron	Phase 3	Recruiting	2026-08	USA, India, China, Germany, Spain, Czechia, Mexico, Japan, South Korea, Taiwan
A Study of Brenipatide in Adult Participants With Major Depressive Disorder NCT07412756 · Depressive Disorder, Major Drug: Brenipatide	Phase 3	Recruiting	2026-02	UK, USA, China, Germany, Spain, Poland, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
A Study of Brenipatide in Adult Participants With Schizophrenia NCT07410507 · Schizophrenia Drug: Brenipatide	Phase 2	Recruiting	2026-02	USA, India, China, Brazil, Japan, Taiwan
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis NCT03773965 · Juvenile Idiopathic Arthritis Drug: Baricitinib	Phase 3	Recruiting	2019-04	UK, India, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Austria, Czechia, Turkey, Brazil, Mexico, Japan, Australia, Israel
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) NCT07165028 · Metabolic Dysfunction-Associated Steatotic Liver Disease Drugs: Retatrutide, Tirzepatide	Phase 3	Recruiting	2025-10	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer NCT06119581 · Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis Drugs: Carboplatin, Cisplatin, Olomorasib	Phase 3	Recruiting	2023-12	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
A Study of LY4088044 in Healthy Participants NCT07090785 · Healthy	Phase 1	Recruiting	2025-07	USA, Singapore
A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity NCT07665879 · ClinicalTrials.gov ↗ · Overweight, Obesity Drug: Eloralintide	Phase 1	Recruiting	2026-06	Germany, Sweden
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease NCT06809400 · Parkinson Disease	Phase 1	Recruiting	2025-02	USA, Japan
Epidemiology and Biomarker Study in Alzheimer's Disease NCT07142954 · Alzheimer Disease	Phase 3	Recruiting	2025-08	USA, Japan
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) NCT07286175 · Bipolar Disorder Drug: Brenipatide	Phase 2	Recruiting	2025-11	USA, India, China, Brazil, Mexico, Japan
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia NCT06721013 · Immune Thrombocytopenia (ITP) Drug: Pirtobrutinib	Phase 1/2	Recruiting	2025-07	UK, USA, China, France, Spain, Italy, Denmark, Poland, Norway, South Korea
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes NCT07668336 · Diabetes Mellitus, Type 2 Drugs: Dulaglutide, Orforglipron	Phase 3	Recruiting	2026-07	UK, USA, India, China, Spain, Italy, Belgium, Brazil, Mexico, Japan, South Korea, Taiwan
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) NCT07533006 · Alopecia Areata Drug: LY4005130	Phase 2	Recruiting	2026-04	UK, USA, China, Netherlands, Poland, Canada, South Korea
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss NCT05821959 · Sensorineural Hearing Loss, Bilateral	Phase 3	Recruiting	2023-09	UK, USA, Canada, Taiwan
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. NCT07401862 · ClinicalTrials.gov ↗ · Hepatic Insufficiency Drug: Eloralintide	Phase 1	Recruiting	2026-02	USA
A Study of LY3439539 in Participants With Alzheimer's Disease NCT07598370 · ClinicalTrials.gov ↗ · Alzheimer Disease	Phase 1	Recruiting	2026-05	USA, Singapore, Australia
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults NCT07222137 · Diabetes Mellitus, Type 1 Drug: Baricitinib	Phase 3	Recruiting	2026-01	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Norway, Portugal, Canada, Brazil, Japan, Australia, Israel
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder NCT07775300 · Depressive Disorder, Major Drug: Brenipatide	Phase 3	Recruiting	2026-08	UK, USA, China, Germany, Spain, Poland, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight NCT07202884 · Urinary Incontinence,Stress Drug: Orforglipron	Phase 3	Recruiting	2025-09	USA, China, Poland, Czechia, Canada, Mexico, Japan, South Korea
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight NCT07369011 · Sleep Apnea, Obstructive, Obesity, Overweight Drug: Eloralintide	Phase 3	Recruiting	2026-02	USA, India, China, Germany, Spain, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder NCT07219966 · Alcohol Use Disorder Drug: Brenipatide	Phase 3	Recruiting	2025-10	UK, USA, China, Germany, Belgium, Japan, South Korea, Taiwan
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) NCT07241390 · Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease Drug: Orforglipron	Phase 3	Recruiting	2025-12	UK, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight NCT07738614 · ClinicalTrials.gov ↗ · Obesity, Overweight Drugs: Acetaminophen, Eloralintide	Phase 1	Recruiting	2026-07	USA, Singapore
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease NCT07483073 · Colitis, Ulcerative, Crohn Disease Drugs: LY4395089, Mirikizumab	Phase 2	Recruiting	2026-05	USA, China, Germany, Italy, Belgium, Poland, Canada, Brazil, Israel
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069 · Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor Drug: Pembrolizumab	Phase 1	Recruiting	2024-07	UK, USA, China, France, Spain, Japan, South Korea, Australia
A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy NCT07808073 · ClinicalTrials.gov ↗ · Obesity, Overweight	Phase 1	Recruiting	2026-09	USA, Singapore
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 NCT05614739 · Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms Drugs: Digoxin, Enfortumab Vedotin, Midazolam	Phase 1	Recruiting	2023-01	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Norway, Canada, Japan, South Korea, Australia, Israel
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) NCT06338995 · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Drug: Lebrikizumab	Phase 3	Recruiting	2024-04	UK, USA, China, Germany, Spain, Italy, Belgium, Denmark, Poland, Portugal, Canada, Mexico, Japan, South Korea, Taiwan
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma NCT06876662 · Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Drug: Pirtobrutinib	Phase 4	Recruiting	2025-05	UK, USA, France, Italy, Poland, Japan, South Korea, Australia
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) NCT07589595 · Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies Drug: Donanemab	Phase 2	Recruiting	2026-05	USA, Japan, South Korea, Taiwan
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight NCT06143956 · ClinicalTrials.gov ↗ · Obesity, Overweight Drugs: Eloralintide, Macupatide, Mazdutide	Phase 2	Recruiting	2023-11	USA
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease NCT07787182 · ClinicalTrials.gov ↗ · Healthy Volunteers, Alzheimer Disease, Amyloid Drug: LY4405094	Phase 1	Recruiting	2025-10	USA, China, Japan
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer NCT06890598 · Carcinoma, Non-Small-Cell Lung Drugs: Durvalumab, Olomorasib, Pembrolizumab	Phase 3	Recruiting	2025-03	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Brazil, Japan, South Korea, Taiwan, Australia, Israel
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers NCT07226843 · Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma Drug: Rituximab	Phase 1	Recruiting	2026-04	UK, USA, Germany, France, Spain, Italy, Poland, Japan
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) NCT06672549 · Obesity, Overweight Drug: Orforglipron	Phase 3	Recruiting	2024-11	UK, USA, China, Spain, Italy, Belgium, Poland, Portugal, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
A Study of Abemaciclib (LY2835219) in Healthy Participants NCT07818967 · ClinicalTrials.gov ↗ · Healthy Volunteers Drug: Abemaciclib	Phase 1	Recruiting	2026-09	Singapore
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event NCT07783802 · Atherosclerosis, Cardiovascular Disease, Obesity Drug: Clazakizumab	Phase 2	Recruiting	2026-08	USA, Japan
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting NCT07613307 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders Drug: Orforglipron	Phase 3	Recruiting	2026-07	India
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease NCT07483099 · Crohn Disease Drugs: LY4395089, Mirikizumab	Phase 2	Recruiting	2026-05	USA, China, Germany, Italy, Belgium, Poland, Canada, Brazil, Israel
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors NCT06561685 · Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Nab-paclitaxel	Phase 1	Recruiting	2024-09	USA, Germany, France, Spain, Japan, South Korea
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib NCT06876649 · Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Drug: Pirtobrutinib	Phase 4	Recruiting	2025-05	UK, USA, France, Italy, Poland, Japan, South Korea, Australia
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) NCT04844606 · Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases Drug: Mirikizumab	Phase 3	Recruiting	2021-05	UK, USA, Germany, Spain, Italy, Netherlands, Belgium, Poland, Austria, Norway, Portugal, Canada, Brazil, Japan, South Korea, Israel
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse NCT07223840 · Smoking Drug: Brenipatide	Phase 2	Recruiting	2025-11	USA, China, Japan
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) NCT07545772 · Irritable Bowel Syndrome, Constipation Drug: Brenipatide	Phase 2	Recruiting	2026-04	UK, USA, China, Spain, Belgium, Canada, Mexico, Japan
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma NCT06517888 · ClinicalTrials.gov ↗ · Vestibular Schwannoma	Phase 1/2	Recruiting	2025-01	USA
A Study of LY4175408 in Participants With Advanced Cancer NCT07046923 · Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms Drugs: Carboplatin, Cisplatin, Pembrolizumab	Phase 1	Recruiting	2025-07	USA, China, France, Spain, Japan, South Korea
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight NCT07353931 · Osteoarthritis, Overweight or Obesity Drug: Eloralintide	Phase 3	Recruiting	2026-02	UK, USA, China, Germany, Belgium, Denmark, Czechia, Canada, Japan, South Korea, Taiwan
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight NCT07589608 · Overweight, Obesity Drugs: Eloralintide, Macupatide	Phase 2	Recruiting	2026-05	USA
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes NCT07881458 · ClinicalTrials.gov ↗ · Obesity, Overweight, Diabetes Mellitus, Type 2 Drugs: Eloralintide and tirzepatide, Tirzepatide	Phase 3	Recruiting	2026-10	USA, China, Germany, Spain, Brazil, Japan, South Korea, Taiwan
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis NCT07100119 · ClinicalTrials.gov ↗ · ALS (Amyotrophic Lateral Sclerosis) Drug: LY4256984	Phase 1	Recruiting	2025-08	Germany, Spain, Netherlands, Belgium, Canada
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer NCT07258836 · Neoplasms, Healthy	Phase 1	Recruiting	2025-12	USA
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer NCT05999994 · Neoplasms, Child, Adolescent Drugs: Abemaciclib, Cyclophosphamide, Docetaxel	Phase 2	Recruiting	2020-01	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Japan, Australia
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) NCT07276958 · ClinicalTrials.gov ↗ · Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis	Phase 1	Recruiting	2026-02	China, Japan, Australia
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide NCT06897475 · Type 2 Diabetes	Phase 2	Recruiting	2025-03	UK, USA, Germany, Poland, Canada
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS) NCT07571200 · ClinicalTrials.gov ↗ · Amyotrophic Lateral Sclerosis Drug: LY4256984	Phase 1	Recruiting	2026-05	Germany, Spain, Netherlands, Belgium, Canada
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata NCT05723198 · Areata Alopecia, Alopecia, Hypotrichosis Drug: Baricitinib	Phase 3	Recruiting	2023-02	USA, Germany, France, Spain, Poland, Canada, Japan, South Korea, Taiwan, Australia
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors NCT07213791 · Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms	Phase 1	Recruiting	2025-10	USA, China, Germany, Netherlands, Japan, Israel
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) NCT06739122 · Type 2 Diabetes Drug: Dulaglutide	Phase 3	Recruiting	2025-01	USA, Mexico
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) NCT07101328 · Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse	Phase 1	Recruiting	2026-05	UK, USA, Germany, France, Spain, Italy, Denmark, Poland, Canada, Japan, South Korea, Australia
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis NCT07258849 · Rheumatoid Arthritis (RA)	Phase 1	Recruiting	2025-12	USA, Germany
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors NCT06400472 · Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms Drugs: Bevacizumab, Carboplatin, Itraconazole	Phase 1	Recruiting	2024-05	USA, France, Spain, Italy, Japan, South Korea, Australia
A Study of Brenipatide in Participants With Opioid Use Disorder NCT07420283 · Opioid Use Disorder Drugs: Brenipatide, Buprenorphine	Phase 2	Recruiting	2026-02	UK, USA, Canada
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) NCT06657768 · Alzheimer Disease, Healthy	Phase 1	Recruiting	2024-10	USA, Japan

Showing the 100 most recently updated of 232 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Eli Lilly and Company in the EU trials register (CTIS)

16 trials · 2 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System with Eli Lilly and Company as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
J2J-MC-JZLL - preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women with Estrogen Receptor-Positive, HER2-Negative Breast Cancer. 2025-523258-15-00 · Neoplasms Drugs: Goserelin, Tamoxifen	Phase 2	Ongoing	Ireland + 4 more
J6M-MC-JSGD: A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2) 2025-522791-92-00 · Neoplasms Drugs: Abemaciclib, Anastrozole, Exemestane	Phase 3	Ongoing	Ireland + 6 more
A Study of LY4152199 in Participants with Previously Treated B-cell Malignancies (BAF_FRontier-1) 2025-524180-20-00 · CTIS ↗ · Neoplasms	Phase 1	Authorised	Italy, France, Denmark + 3 more
J2A-MC-GZVA:A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared with Placebo in Individuals with Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity 2026-526175-35-00 · CTIS ↗ · Nutritional and Metabolic Diseases Drug: Orforglipron	Phase 3	Ongoing	Czechia, Germany, Spain
J3R-MC-YDAS: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk 2026-525919-14-00 · CTIS ↗ · Nutritional and Metabolic Diseases Drug: Eloralintide	Phase 3	Authorised	Spain, Poland, France + 5 more
J2A-MC-GZGY: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes 2025-524811-35-00 · Nutritional and Metabolic Diseases Drugs: Dulaglutide, Orforglipron	Phase 3	Ongoing	Italy, Spain, Belgium
A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA 2026-525574-19-00 · Nervous System Diseases	Phase 1	Authorised	Netherlands, Belgium, Germany + 1 more
J2S-MC-GZMV: A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) 2026-525480-41-00 · Respiratory Tract Diseases Drug: Brenipatide	Phase 2	Ongoing	Denmark, France, Romania + 5 more
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers 2025-523601-16-00 · Hemic and Lymphatic Diseases	Phase 1	Authorised	Spain, Poland, Italy + 2 more
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis 2025-523980-39-00 · Immune System Diseases	Phase 1	Authorised	Germany
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (FiREBOLT) 2025-521887-37-00 · Neoplasms	Phase 1	Authorised	Germany, Netherlands
J6Z-MC-IIBD - A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease J6Z-MC-CD01 - A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared with Mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease 2025-524112-11-00 · CTIS ↗ · Digestive System Diseases Drug: Mirikizumab	Phase 2	Ongoing	Italy, Germany, Hungary + 2 more
A Study to Evaluate Mirikizumab Concentrations in Breast Milk Following Administration of Mirikizumab by Subcutaneous Injection in Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication 2025-522362-78-00 · CTIS ↗ · Immune System Diseases Drug: Mirikizumab	Phase 4	Ongoing	Spain, Denmark, Germany + 2 more
J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration. 2025-522855-25-00 · CTIS ↗ · Neoplasms Drugs: Enfortumab Vedotin, Pembrolizumab	Phase 3	Ongoing	Italy, Poland, Denmark + 6 more
A Study of LY4257496 in Participants With Cancer (OMNIRAY) 2025-522367-15-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Germany
I4V-MC-JAJJ: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to <36 Years 2025-521797-34-00 · CTIS ↗ · Immune System Diseases Drug: Baricitinib	Phase 3	Ongoing	Belgium, Spain, Norway + 8 more

Drugs in Eli Lilly and Company trials

108 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 68 more in the trial list above.

By trial register

Register	Trials	Recruiting
Clinical trials in USA	201	109
Clinical trials in Japan	117	67
Clinical trials in Spain	100	48
Clinical trials in Germany	98	50
Clinical trials in China	94	53
Clinical trials in Canada	83	45
Clinical trials in France	79	36
Clinical trials in UK	75	46
Clinical trials in Italy	74	37
Clinical trials in Poland	71	42
Clinical trials in South Korea	70	40
Clinical trials in Australia	66	31
Clinical trials in Belgium	62	35
Clinical trials in Taiwan	59	32
Clinical trials in Mexico	56	27
Clinical trials in Brazil	51	31
Clinical trials in Czechia	48	20
Clinical trials in Netherlands	44	26
Clinical trials in Israel	44	23
Clinical trials in India	42	20
Clinical trials in Denmark	32	14
Clinical trials in Turkey	32	12
Clinical trials in Austria	27	14
Clinical trials in Singapore	25	11
Clinical trials in Portugal	13	11
Clinical trials in Sweden	12	6
Clinical trials in Norway	11	10
Clinical trials in Ireland	9	5
Clinical trials in Switzerland	9	4
Clinical trials in Egypt	1	0
EU register (CTIS)	16	—

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Obesity

Sponsor	Trials
Novo Nordisk	63
Pfizer	14
Boehringer Ingelheim	10
Amgen	9
Cairo University	9
Istituto Auxologico Italiano	8
Assistance Publique - Hôpitaux de Paris	8
China-Japan Friendship Hospital	6
Kailera	5
Innovent Biologics (Suzhou)	5

Sponsors with the most current trials registered for this condition.

Questions about Eli Lilly and Company trials

How many clinical trials does Eli Lilly and Company sponsor?

Eli Lilly and Company is the lead sponsor of 232 current trials on ClinicalTrials.gov in our USA, Japan, Spain, Germany, China, Canada, France, UK, Italy, Poland, South Korea, Australia, Belgium, Taiwan, Mexico, Brazil, Czechia, Netherlands, Israel, India, Denmark, Turkey, Austria, Singapore, Portugal, Sweden, Norway, Ireland, Switzerland and Egypt registers, and 16 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Eli Lilly and Company trials recruiting?

Yes. 122 of its 232 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Eli Lilly and Company testing?

Its current trials name 108 drugs and biologicals as interventions. The most frequent are Tirzepatide (22), Abemaciclib (20), Orforglipron (19), Eloralintide (18) and Brenipatide (15). The number in brackets is how many of its trials name each drug.

Does Eli Lilly and Company have clinical trials in Ireland?

Yes. 9 trials in our Ireland register (ClinicalTrials.gov), and 2 trials in the EU register (CTIS) with a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.